JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

VEGFR

VEGFR are receptors for vascular endothelial growth factor and belong to receptor tyrosine kinases.

A3009 Sorafenib
2 Citation

Target: Raf|VEGFR

Summary: Raf kinases and tyrosine kinases inhibitor

≥23.25 mg/mL
A3022 Pazopanib (GW-786034)

Target: CSF-1R|VEGFR|PDGFR|c-Kit|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in EtOH; insoluble in H2O; ≥10.95 mg/mL
B5864 Fruquintinib(HMPL-013)

Target: VEGFR

Summary: Potent and selective inhibitor of VEGFR 1, 2, 3

insoluble in H2O; insoluble in EtOH; ≥6.35 mg/mL
B5953 Dovitinib (TKI258) Lactate

Target: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).

insoluble in EtOH; ≥10.62 mg/mL
C3342 MAZ51

Target: VEGFR

Summary: VEGFR3 antagonist

insoluble in EtOH; insoluble in H2O; ≥31.4 mg/mL
A3750 Regorafenib hydrochloride

Target: Raf|VEGFR|PDGFR|c-Kit|c-RET

Summary: Tyrosine kinase inhibitor

≥25.95 mg/mL
A3969 Vatalanib
1 Citation

Target: VEGFR

Summary: VEGFR-1/-2 inhibitor,cell-permeable

≥16.85 mg/mL
A8236 Regorafenib
4 Citation

Target: Raf|VEGFR|PDGFR|c-Kit|RET

Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

≥25.04 mg/mL
A8252 Nintedanib (BIBF 1120)
3 Citation

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
A2949 Linifanib (ABT-869)

Target: VEGFR|PDGFR

Summary: VEGFR/PDGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥18.75 mg/mL